Affinage

BMX

Cytoplasmic tyrosine-protein kinase BMX · UniProt P51813

Length
675 aa
Mass
78.0 kDa
Annotated
2026-04-28
100 papers in source corpus 44 papers cited in narrative 43 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

BMX (also called Etk) is a Tec-family nonreceptor tyrosine kinase that integrates signals from PI3K, receptor tyrosine kinases (VEGFR2, Tie-2, EGFR), FAK/Src, TNFR2, and G-protein-coupled receptors to regulate endothelial cell migration, angiogenesis, inflammatory cytokine production, cardiac hypertrophy, and cancer cell survival. Activated by PI3K-dependent membrane translocation via its PH domain or by Src-mediated transphosphorylation at Tyr566, BMX preferentially phosphorylates substrates containing a priming phosphotyrosine (pYY motif), thereby amplifying RTK activation loops and downstream AKT signaling; it also directly activates STAT3 (bypassing SOCS3 in glioblastoma stem cells), phosphorylates PAR1 to promote its internalization and attenuate vascular permeability, phosphorylates BAK to suppress apoptosis, and phosphorylates 3βHSD1 at Y344 to drive androgen biosynthesis in castration-resistant prostate cancer (PMID:9520419, PMID:23716717, PMID:29848664, PMID:31910739, PMID:25649765, PMID:36647826). Beyond its catalytic roles, BMX functions as a kinase-independent scaffold within the TAK1-TAB signaling complex to mediate inflammatory NF-κB/MAPK signaling, as demonstrated by the differential phenotypes of Bmx-knockout versus kinase-inactive knock-in mice in arthritis models (PMID:21471444). In vivo, Bmx-knockout mice exhibit impaired ischemia-induced arteriogenesis, resistance to pressure overload-induced cardiac hypertrophy, and increased vascular permeability during sepsis, while BMX upregulation under androgen deprivation or hypoxia drives therapy resistance in prostate cancer and AML (PMID:16932810, PMID:18988895, PMID:30012673, PMID:29227282).

Mechanistic history

Synthesis pass · year-by-year structured walk · 20 steps
  1. 1994 Medium

    Identification of BMX as a new Tec-family kinase with intrinsic tyrosine kinase activity established its membership in the nonreceptor tyrosine kinase superfamily and set up the question of what upstream signals activate it and what substrates it phosphorylates.

    Evidence Molecular cloning and phosphotyrosine detection in COS cell immunoprecipitates

    PMID:7970727

    Open questions at the time
    • Single lab; no upstream activator or substrate identified
    • No endogenous expression context defined
  2. 1998 High

    Demonstrating that PI3K activates BMX and that BMX translocates to membranes upon PI3K activation resolved the upstream activation mechanism and linked BMX to PH-domain-dependent lipid signaling, analogous to Btk.

    Evidence Wortmannin inhibition, dominant-active/negative PI3K subunits, and GFP-tagged membrane translocation in prostate cancer and myeloid cells

    PMID:10962576 PMID:9520419

    Open questions at the time
    • Whether PH-domain lipid binding is PIP3-specific was not resolved
    • Redundancy with other Tec kinases in PI3K-dependent contexts unclear
  3. 1997 High

    Showing that BMX directly activates STAT1, STAT3, and STAT5 independently of JAK kinases established STAT activation as a core BMX output, opening the question of whether BMX bypasses normal JAK-STAT regulatory checkpoints.

    Evidence Transfection in mammalian/insect cells, EMSA, reporter assays, selective inhibition by PKCδ

    PMID:9373245

    Open questions at the time
    • Direct phosphorylation of STAT by BMX not shown with purified components
    • Physiological context of JAK-independent STAT activation not defined
  4. 2000 High

    Discovery that v-Src transphosphorylates BMX at Tyr566 to trigger autophosphorylation, and that BMX mediates Src-to-STAT3 signaling for transformation, established BMX as a relay between Src and STAT3 and identified the key activating phosphosite.

    Evidence Co-immunoprecipitation, site-directed mutagenesis of Tyr566, dominant-negative epistasis, transformation assays

    PMID:10688651

    Open questions at the time
    • Whether Tyr566 phosphorylation recruits specific SH2-containing partners besides PI3K p85 was resolved only later
  5. 2001 High

    Mapping the FAK–BMX interaction (PH domain to FERM domain) and showing it is required for ECM-induced Etk activation and cell migration established the integrin/FAK axis as a PI3K-independent activation route for BMX.

    Evidence Co-immunoprecipitation, FAK-null cell complementation, domain mutants, migration assays

    PMID:11331870 PMID:11713275

    Open questions at the time
    • Whether FAK directly phosphorylates BMX or acts solely as a scaffold was not resolved
    • Structural basis of PH-FERM interaction unknown
  6. 2001 High

    Identifying BMX association with Tie-2 and VEGFR-1 in arterial endothelium, and showing that Bmx-KO mice are viable, established BMX as an endothelial signaling kinase with functional redundancy during normal vascular development.

    Evidence lacZ knock-in mouse, receptor-specific kinase activation assays

    PMID:11416142

    Open questions at the time
    • Identity of compensating kinase(s) in KO not determined
    • Stress-specific phenotypes not yet tested
  7. 2002 High

    Demonstrating that BMX forms a ligand-independent complex with TNFR2 (not TNFR1) and mediates TNF-induced endothelial migration/tube formation resolved how BMX connects to inflammatory cytokine signaling and identified a non-canonical TNF receptor pathway.

    Evidence Reciprocal co-immunoprecipitation, TNFR2-null cells, domain mapping, migration/tube formation assays

    PMID:12370298

    Open questions at the time
    • Whether TNFR2–BMX complex signals independently of NF-κB not fully dissected
    • Structural basis of the TNFR2 C-terminal 16aa interaction unknown
  8. 2003 High

    Showing that BMX phosphorylates p130Cas to promote Cas–Crk complex formation and membrane ruffling established a direct mechanistic link between BMX and actin remodeling/cell migration.

    Evidence Co-immunoprecipitation at membrane ruffles, mutant BMX unable to bind Cas fails to induce migration, dominant-negative Cas epistasis

    PMID:12832404

    Open questions at the time
    • Specific tyrosine residue(s) on Cas phosphorylated by BMX not identified
  9. 2004 High

    Discovery of bidirectional BMX–p53 regulation—p53 inhibits BMX kinase activity while BMX inhibits p53 transcriptional and mitochondrial apoptotic functions—revealed a mutual antagonism governing the balance between survival and apoptosis.

    Evidence SH3 domain array screening, co-immunoprecipitation, siRNA, reporter and apoptosis assays

    PMID:15355990

    Open questions at the time
    • Whether BMX directly phosphorylates p53 was not shown
    • In vivo relevance of BMX–p53 axis not tested in genetic models
  10. 2006 High

    In vivo demonstration that Bmx-KO impairs ischemia-induced arteriogenesis while endothelial-specific constitutively active Bmx enhances it established BMX as a critical mediator of postnatal angiogenesis under stress, dependent on bone marrow-derived cells.

    Evidence Bmx-KO and Tie-2 promoter-driven transgenic mice, hindlimb ischemia, bone marrow transplantation

    PMID:16932810

    Open questions at the time
    • Specific bone marrow cell population mediating BMX-dependent remodeling not identified
  11. 2008 High

    Demonstrating that Bmx-KO mice are protected from inflammatory arthritis while kinase-inactive knock-in mice are not established that BMX has kinase-independent scaffolding functions within the TAK1-TAB signaling complex for NF-κB/MAPK activation.

    Evidence Bmx-KO and kinase-inactive knock-in mice, K/BxN serum-transfer arthritis, PH domain mutants with myristylation rescue, reporter assays

    PMID:21471444

    Open questions at the time
    • The precise TAK1-TAB interaction surface on BMX not mapped
    • Whether the scaffold function is PH-domain-dependent or requires other domains not fully resolved
  12. 2008 High

    Showing that Bmx-KO mice resist pressure overload-induced cardiac hypertrophy established BMX as a necessary mediator of pathological cardiac remodeling, expanding its in vivo relevance beyond vasculature.

    Evidence Bmx-KO mice with transverse aortic constriction, echocardiography, histomorphometry

    PMID:18988895

    Open questions at the time
    • Whether the cardiac role is cardiomyocyte-autonomous or endothelial not distinguished
  13. 2011 High

    Establishing that BMX activates STAT3 to maintain glioblastoma stem cell self-renewal, with constitutively active STAT3 rescuing BMX knockdown, defined BMX as a non-redundant upstream kinase in cancer stem cell biology.

    Evidence shRNA, constitutively active STAT3 rescue, neurosphere formation, intracranial tumor model

    PMID:21481791

    Open questions at the time
    • Whether BMX directly phosphorylates STAT3 Y705 or acts through an intermediate not resolved
  14. 2013 High

    Substrate specificity profiling revealed that BMX preferentially phosphorylates a priming pYY motif, establishing it as an amplifier of RTK activation loops (e.g., FAK Tyr577 after Src-mediated Tyr576 phosphorylation) and explaining its broad RTK-amplifying activity.

    Evidence Positional scanning peptide library, in vitro kinase assay, Bmx-KO MEFs with site-specific phospho-antibodies

    PMID:23716717

    Open questions at the time
    • Full catalog of endogenous pYY substrates not determined
    • Structural basis for pY-1 recognition not solved
  15. 2015 High

    Identifying BAK as a direct BMX substrate whose phosphorylation suppresses apoptotic activation revealed a mechanism by which BMX confers chemoresistance and linked BMX to mitochondrial apoptotic regulation.

    Evidence Co-immunoprecipitation, in vitro kinase assay, siRNA with BAK activation and apoptosis assays

    PMID:25649765

    Open questions at the time
    • Specific BAK tyrosine residue phosphorylated not identified in this study
    • In vivo relevance in tumor models not tested
  16. 2018 High

    Demonstrating that BMX bypasses SOCS3-mediated JAK2 inhibition to activate STAT3 in glioblastoma stem cells provided the mechanistic explanation for why BMX-expressing cancer stem cells are resistant to normal cytokine feedback, making BMX a selective therapeutic target.

    Evidence Ibrutinib pharmacological inhibition, shRNA, SOCS3 epistasis, intracranial tumor models with radiotherapy

    PMID:29848664

    Open questions at the time
    • Whether BMX physically interacts with SOCS3 or simply circumvents it by acting on a different STAT3 pool not resolved
  17. 2018 High

    Showing that AR directly represses BMX transcription and that androgen deprivation upregulates BMX to amplify RTK pYY motif phosphorylation explained the molecular basis for BMX's role in castration-resistant prostate cancer.

    Evidence AR ChIP at BMX locus, anti-pYpY antibody, xenograft with castration plus BMX inhibitors

    PMID:30012673

    Open questions at the time
    • Full set of RTKs amplified by BMX in CRPC not cataloged
    • Whether HIF also contributes to BMX upregulation under androgen deprivation not tested
  18. 2020 High

    Identifying PAR1 as a direct BMX substrate whose phosphorylation promotes receptor internalization to limit vascular permeability established a protective endothelial role for BMX in sepsis, distinct from its pro-inflammatory functions.

    Evidence BMX-KO mice, cecal ligation/puncture sepsis model, transendothelial resistance, PAR1 phosphorylation/internalization assays, PAR1 antagonist rescue

    PMID:31910739

    Open questions at the time
    • Specific PAR1 tyrosine(s) phosphorylated by BMX not mapped
    • Whether BMX regulates other thrombin receptors (PAR3, PAR4) not tested
  19. 2020 High

    The X-ray crystal structure of BMX bound to a covalent inhibitor at Cys496 revealed a DFG-out-like inactive conformation and key catalytic residue interactions, providing the structural foundation for selective inhibitor design.

    Evidence X-ray crystallography, molecular dynamics, kinome selectivity profiling, cellular target engagement

    PMID:34458764

    Open questions at the time
    • No structure of active-state BMX available
    • PH-domain-mediated autoinhibition structural mechanism not resolved
  20. 2023 High

    Discovery that BMX phosphorylates 3βHSD1 at Y344 to activate its steroidogenic activity directly linked BMX kinase activity to androgen biosynthesis, revealing a non-RTK metabolic substrate and a druggable node in castration-resistant prostate cancer.

    Evidence Co-immunoprecipitation, in vitro kinase assay, Y344 mutagenesis, patient tissue analysis, in vivo CRPC xenograft

    PMID:36647826

    Open questions at the time
    • Whether BMX regulates other steroidogenic enzymes unknown
    • Whether 3βHSD1 Y344 contains a priming pY motif consistent with the pYY rule not assessed

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include the structural basis for PH-domain-mediated autoinhibition, the full catalog of endogenous pYY substrates, the mechanism distinguishing kinase-dependent from scaffold-dependent functions in specific tissues, and how BMX's protective (PAR1/vascular barrier) and pathological (STAT3/cancer stem cell, androgen biosynthesis) outputs are differentially regulated.
  • No full-length active-state crystal structure
  • Comprehensive pYY substrate proteomics not performed
  • Tissue-specific regulation of kinase vs. scaffold functions unresolved

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 6 GO:0098772 molecular function regulator activity 3 GO:0060090 molecular adaptor activity 1
Localization
GO:0005886 plasma membrane 3 GO:0005829 cytosol 2
Pathway
R-HSA-162582 Signal Transduction 9 R-HSA-1643685 Disease 4 R-HSA-168256 Immune System 4 R-HSA-5357801 Programmed Cell Death 4 R-HSA-1266738 Developmental Biology 2
Partners
BAK1FAKHSD3B1P130CASPAR1STAT3TP53VEGFR2
Complex memberships
PKC-ε signaling complexTAK1-TAB complexTNFR2-Etk complex

Evidence

Reading pass · 43 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1994 BMX encodes a nonreceptor tyrosine kinase with PH, SH3, SH2, and catalytic domains; immunoprecipitates from COS cells transfected with BMX contain a tyrosyl-phosphorylated BMX polypeptide (~80 kDa), demonstrating intrinsic kinase activity. Molecular cloning, transfection, immunoprecipitation with phosphotyrosine detection Oncogene Medium 7970727
1997 BMX (Bmx) induces tyrosine phosphorylation and DNA-binding activity of STAT1, STAT3, and STAT5, and activates STAT-dependent reporter genes independently of endogenous JAK kinases; this activity is selectively inhibited by PKCδ, which blocks STAT1 tyrosine phosphorylation downstream of Bmx. Transient transfection in mammalian and insect cells, reporter gene assays, dominant-negative PKC isoforms Blood High 9373245
1998 Etk/BMX is an effector of PI3-kinase: PI3-kinase inhibitor wortmannin abolishes IL-6-induced Etk activation, constitutively active p110 activates Etk without IL-6, and dominant-negative p85 blocks IL-6-induced Etk activation; active Etk is required for IL-6-induced neuroendocrine differentiation of prostate cancer cells. Pharmacological inhibition (wortmannin), dominant-active/dominant-negative PI3K subunits, dominant-negative Etk overexpression Proceedings of the National Academy of Sciences of the United States of America High 9520419
1998 Bmx and Tec activate serum response factor (SRF) in synergy with constitutively active Gα12/13, in a Rho-dependent (C3-sensitive) manner; the kinase and TH domains of Bmx are required for SRF activation; kinase-dead Bmx inhibits Gα12/13-induced and thrombin-induced SRF activation. Transient transfection in NIH 3T3 cells, C3 toxin treatment, domain mutants, dominant-negative kinase The EMBO journal High 9755164
1999 BMX reconstitutes PLCγ2-dependent signaling (calcium mobilization, ERK/MAPK activation, and apoptosis) in Btk-deficient DT40 B cells, demonstrating functional equivalence to other Tec kinases in BCR signaling; this reconstitution requires PI3K (and implicitly the PH domain), placing BMX downstream of PI3K in B-cell signaling. Genetic reconstitution of Btk-deficient DT40 cells, calcium flux, ERK activation assays The Journal of biological chemistry High 10224128
2000 v-Src transphosphorylates Etk/BMX at tyrosine 566, inducing subsequent autophosphorylation and increased kinase activity; activated Etk associates with STAT3 in vivo and links Src to STAT3 activation; dominant-negative Etk blocks v-Src-induced STAT3 phosphorylation and substantially reduces v-Src-induced cellular transformation. Co-transfection, co-immunoprecipitation, dominant-negative mutants, transformation assays in WB and NIH3T3 cells Molecular and cellular biology High 10688651
2000 Bmx is catalytically activated by IL-3 and G-CSF receptors in a PI3K-dependent manner; GFP-Bmx translocates to cellular membranes upon co-expression of constitutively active PI3K; wild-type Bmx expression in 32D myeloid cells promotes apoptosis in the presence of G-CSF, while kinase-dead Bmx allows granulocyte differentiation. PI3K inhibitor treatment, GFP-tagged membrane translocation assay, kinase-dead mutant overexpression in myeloid cells Oncogene High 10962576
2001 Etk/BMX interacts with FAK through the PH domain of Etk and the FERM domain of FAK; this interaction is required for Etk activation by extracellular matrix proteins and for cell migration; disrupting the Etk-FAK interaction or re-introducing wild-type FAK into FAK-null cells modulates Etk activation and cell migration. Co-immunoprecipitation, FAK-null cell complementation, domain mutants, antisense oligonucleotides, migration assays Nature cell biology High 11331870
2001 Etk/BMX directly associates with Pak1 via its N-terminal PH domain and phosphorylates Pak1 on tyrosine residues, establishing Pak1 as a substrate; wild-type Etk promotes proliferation and anchorage-independent growth in MCF-7 cells, while kinase-inactive Etk-KQ suppresses these phenotypes in MDA-MB-435 cells. Co-immunoprecipitation, GST pulldown, in vitro kinase assay, overexpression and dominant-negative in breast cancer cell lines The Journal of biological chemistry High 11382770
2001 Etk/BMX is activated by FAK and Src downstream of bombesin/neuropeptide-coupled G-protein receptors; Etk activation requires FAK and Src but not PI3K in this context; dominant-negative Etk blocks bombesin-induced LNCaP cell growth and androgen receptor transactivation, placing Etk in the FAK→Src→Etk→AR pathway for androgen-independent growth. Dominant-negative kinase constructs, pharmacological inhibitors, reporter gene assays, growth assays Molecular and cellular biology High 11713275
2001 Native Bmx associates with endogenous caveolin-1 in human umbilical vein endothelial cells; caveolin-1 expression reduces tyrosine phosphorylation of Btk/Bmx in vivo, and the caveolin-1 scaffolding peptide (aa 82–101) suppresses the autokinase activity of purified Btk, identifying caveolin-1 as a negative regulator of Tec kinase activity. Co-immunoprecipitation from primary endothelial cells, in vitro kinase assay with scaffolding peptide, transient co-transfection The Journal of biological chemistry Medium 11751885
2001 Bmx tyrosine kinase is expressed downstream of activated Tie-2 and VEGFR-1 receptors in arterial endothelium; activated Tie-2 induces tyrosyl phosphorylation of Bmx protein and both Tie-2 and VEGFR-1 stimulate Bmx tyrosine kinase activity; Bmx knockout mice are viable with normal life span, indicating redundancy in vascular development. lacZ knock-in mouse, co-expression and kinase activity assays downstream of Tie-2/VEGFR-1 Molecular and cellular biology High 11416142
2002 Etk/BMX forms a preexisting complex with TNFR2 (not TNFR1) in a ligand-independent manner through multiple Etk domains (PH, TH, SH2) and the C-terminal 16 aa of TNFR2; TNF activates Etk specifically via TNFR2; TRAF2 is not involved in this activation; constitutively active Etk enhances, and dominant-negative Etk blocks, TNF-induced endothelial cell migration and tube formation. Co-immunoprecipitation, TNFR2-specific agonist, TNFR2-deficient cells, domain mapping, migration/tube formation assays Molecular and cellular biology High 12370298
2002 Etk/BMX selectively activates RhoA (but not Cdc42 or Rac1) through its PH domain; Etk and RhoA co-translocate to the plasma membrane and form a complex upon serum stimulation; Etk disrupts RhoA–Rho-GDI interaction, promoting RhoA membrane translocation and downstream stress fiber formation. Co-immunoprecipitation, GFP-tagged localization, GDI dissociation assay, PH-domain mutants, stress fiber assay The Journal of biological chemistry High 12023958
2002 Etk/BMX interacts with RUFY1 (a RUN/FYVE domain-containing endosomal protein) through Etk's SH3 and SH2 domains; Etk phosphorylates RUFY1 on tyrosine, and phosphorylation is required for RUFY1 endosomal localization; Etk overexpression increases plasma membrane EGFR and delays EGF-induced receptor endocytosis. Yeast two-hybrid, co-immunoprecipitation, in vitro kinase assay, subcellular localization (EEA1 co-localization), EGFR endocytosis assay The Journal of biological chemistry Medium 11877430
2003 Bmx/Etk interacts with the docking protein p130Cas at membrane ruffles; Bmx enhances tyrosine phosphorylation of Cas and Cas–Crk complex formation; a Bmx mutant that fails to interact with Cas fails to induce cell migration; dominant-negative Cas inhibits Bmx-induced membrane ruffling and cell migration, establishing the Bmx→Cas→Crk axis in actin remodeling and motility. Co-immunoprecipitation, co-localization at membrane ruffles, phosphorylation assay, mutant Bmx and dominant-negative Cas, haptotactic migration assay The Journal of biological chemistry High 12832404
2003 TNF induces coordinated phosphorylation and complex formation between Etk and VEGFR2, resulting in reciprocal transactivation; Etk phosphorylation at Tyr-566 directly mediates recruitment of the PI3K p85 subunit; Etk-deficient endothelial cells show blunted TNF-induced VEGFR2, Akt activation, and cell migration, independently of VEGF-induced VEGFR2 signaling. VEGFR2 inhibitors, co-immunoprecipitation, site-specific mutants (Tyr-566), Etk-null endothelial cells, migration assays The Journal of biological chemistry High 14532277
2004 Etk/BMX is physically associated with p53 through the SH3 domain of Etk and the proline-rich domain of p53; p53 induction by DNA damage inhibits Etk activity; Etk inhibits p53 transcriptional activity and its interaction with mitochondrial BAK; the interaction is bidirectional, with each protein inhibiting the other's activity. SH3 domain array screening, co-immunoprecipitation, kinase activity assay, reporter gene assay, siRNA knockdown, apoptosis assay The Journal of biological chemistry High 15355990
2001 Caspase cleavage of Etk/BMX generates a C-terminal fragment (containing intact SH2 and kinase domains but lacking the PH and SH3 domains) with ~4-fold higher kinase activity than full-length Etk; ectopic expression of this fragment sensitizes PC3 cells to apoptosis-inducing stimuli. In vitro translation with caspase incubation, recombinant caspases, kinase activity assay, ectopic fragment expression with apoptosis readout The Journal of biological chemistry High 11278797
2006 The 44 kDa Pim-1 isoform directly binds the SH3 domain of Etk/BMX through its N-terminal proline-rich motif, activating Etk kinase activity, possibly by competing with tumor suppressor p53 for SH3 binding; this interaction confers resistance to chemotherapeutic drugs in prostate cancer cells. Co-immunoprecipitation, GST pulldown, kinase activity assay, ectopic overexpression in prostate cancer cell lines Oncogene Medium 16186805
2006 Bmx/Etk is required for ischemia-mediated arteriogenesis and angiogenesis in vivo; Bmx-KO mice show markedly reduced, and Bmx-transgenic mice (constitutively active Bmx under Tie-2 promoter) show enhanced, clinical recovery and limb perfusion after ischemia; bone marrow transplantation shows Bmx in bone marrow-derived cells is critical for early ischemic tissue remodeling; Bmx mediates TNFR2/VEGFR2 angiogenic signaling. Bmx-KO and Bmx-transgenic mice, hindlimb ischemia model, bone marrow transplantation, immunofluorescence, signaling assays The Journal of clinical investigation High 16932810
2007 Bmx regulates TLR4-induced IL-6 production in human macrophages by stabilizing IL-6 mRNA via the 3' UTR through a p38 MAPK-independent pathway; Btk knockdown reduces TNFα but not IL-6, distinguishing Bmx's specific role in IL-6 regulation. siRNA knockdown, cytokine ELISA, mRNA stability assay targeting the 3' UTR, p38 inhibitor treatment Blood Medium 18025155
2008 BMX is required for phosphorylation of p38 MAPK and JNK, and activation of NF-κB downstream of TNF, IL-1β, and TLR agonists; BMX acts at the level of the TAK1-TAB complex; membrane association via the PH domain (replaceable by myristylation signal) and kinase activity are both required for IL-8 promoter activation; Bmx-KO mice are protected from passive K/BxN serum-transfer arthritis, but kinase-inactive knock-in mice are not protected, revealing kinase-independent scaffolding functions. siRNA knockdown, PH domain mutants, myristylation-signal substitution, reporter assay, Bmx-KO and kinase-inactive knock-in mouse arthritis model Journal of immunology High 21471444
2008 BMX interacts with FAK and Mal (a TLR adaptor) as well as MyD88, as shown by co-immunoprecipitation in fibroblast-like synoviocytes; LPS and fibronectin-derived protein I/II-induced phosphorylation of Etk and Mal are FAK-dependent; Etk and Mal are required for IL-6 synthesis downstream of the integrin/FAK and MyD88 pathways. Co-immunoprecipitation, siRNA knockdown, phosphorylation assay, IL-6 ELISA in rheumatoid fibroblast-like synoviocytes Journal of immunology Medium 18292575
2008 BMX forms a complex with STAT3 in pressure-overloaded cardiomyocyte myocardium (detected in detergent-insoluble fractions); RGD-integrin stimulation activates BMX and redistributes it with STAT3 in a JAK2-independent manner; c-Src dominant-negative does not block RGD-stimulated BMX or STAT3 activation, indicating BMX acts independently of Src in this context. In vivo pressure-overload model, fractionation, co-immunoprecipitation, dominant-negative adenovirus, in vitro cardiomyocyte RGD stimulation International journal of biological sciences Medium 18612371
2008 Bmx is a member of the PKC-ε signaling complex in the heart; Bmx is activated by nitric oxide in rabbit heart concomitant with the late phase of NO-donor-induced cardioprotection; increased Bmx expression induced by NO donors is blocked by PKC inhibition with chelerythrine. Functional proteomic analysis of PKC-ε complexes, in vivo rabbit NO-donor treatment, PKC inhibitor (chelerythrine) American journal of physiology. Heart and circulatory physiology Medium 15191890
2008 Loss of Bmx prevents pressure overload-induced cardiac hypertrophy and preserves ejection fraction in mice; Bmx-KO mice are resistant to transverse aortic constriction-induced cardiac growth at the organ and cell level, establishing Bmx as a necessary regulator of hypertrophic signaling in the heart. Bmx-KO mice, transverse aortic constriction model, echocardiography, histology Circulation research High 18988895
2010 Etk/BMX directly interacts with androgen receptor (AR) through its SH2 domain; this interaction prevents AR-Mdm2 association, stabilizing AR under androgen-depleted conditions; Etk overexpression increases AR tyrosine phosphorylation, and Etk is upregulated in prostates in response to androgen ablation. Co-immunoprecipitation (domain mapping with SH2), phosphorylation assay, siRNA knockdown, tissue microarray IHC (Pearson correlation), xenograft model Cancer research High 20570899
2011 BMX activates STAT3 to maintain self-renewal and tumorigenic potential of glioblastoma stem cells (GSCs); BMX knockdown inhibits STAT3 activation and GSC transcription factor expression; constitutively active STAT3 rescues BMX knockdown effects, placing BMX upstream of STAT3 in GSC maintenance. shRNA knockdown, constitutively active STAT3 rescue, intracranial tumor growth assay, neurosphere formation Cancer cell High 21481791
2013 BMX preferentially phosphorylates substrates containing a priming phosphotyrosine (pY) at the −1 position (pYY motif); BMX phosphorylates FAK at Tyr577 subsequent to Src-mediated phosphorylation at Tyr576, generating the pYpY activation motif; BMX deficiency (RNAi or KO) impairs FAK and insulin receptor activation loop phosphorylation and downstream AKT Thr308 phosphorylation. Positional scanning peptide library, in vitro kinase assay, RNAi, Bmx-KO MEFs and liver tissue, phospho-specific antibodies Science signaling High 23716717
2013 BMX covalently and irreversibly modifies Cys496 in the ATP-binding pocket using electrophilic inhibitors (BMX-IN-1), and clinical EGFR inhibitors (e.g., CI-1033) also irreversibly modify BMX at Cys496; this identifies Cys496 as the critical covalent modification site for BMX inhibition. Covalent inhibitor design, kinome profiling, structure-based drug design, cell viability assays ACS chemical biology High 18667312 23594111
2015 BMX directly associates with BAK in viable cells and phosphorylates a key tyrosine on BAK to maintain it in an inactive conformation; elevated BMX prevents BAK activation in tumor cells treated with chemotherapy, and BMX silencing potentiates BAK activation and sensitizes tumor cells to chemotherapeutic agents. Co-immunoprecipitation, in vitro kinase assay for BAK phosphorylation, siRNA knockdown with apoptosis/BAK activation assays Cancer research High 25649765
2015 Endothelial Bmx kinase activity is required for angiotensin II-induced cardiac hypertrophy; Bmx-kinase-inactive knock-in mice show significantly reduced Ang II-induced hypertrophy; Ang II stimulates Bmx phosphorylation in endothelial cells and Bmx silencing inhibits downstream STAT3 signaling; Bmx inactivation suppresses Ang II-induced mTORC1 pathway activation. Kinase-inactive Bmx knock-in mice, Ang II infusion, Bmx siRNA in endothelial cells, genome-wide transcriptomic profiling, phospho-signaling assays Proceedings of the National Academy of Sciences of the United States of America High 26430242
2016 BMX promotes N-end rule proteasomal degradation of the pro-apoptotic caspase-generated BMX C-terminal fragment via its N-terminal tryptophan; phosphorylation of Tyr566 on this fragment inhibits its N-end rule degradation and is required for its pro-apoptotic function. In-cell pulse-chase/metabolic stability assay, proteasome inhibitors, N-end rule pathway analysis, phospho-mutant constructs in PC3 cells The Journal of biological chemistry Medium 27601470
2017 Hypoxia induces HIF-dependent BMX upregulation in AML cells; BMX acts as a compensatory prosurvival kinase through STAT5 signaling during FLT3 inhibition with sorafenib; pharmacological inhibition or genetic knockout of BMX reverses this resistance phenotype in FLT3-ITD+ cell lines. RNA-Seq of patient samples, in vivo murine FLT3-ITD model, hypoxia in vitro experiments, pharmacological BMX inhibition, genetic KO, pSTAT5 signaling assay The Journal of clinical investigation High 29227282
2018 BMX inhibition by ibrutinib disrupts BMX-mediated STAT3 activation in GSCs; BMX bypasses SOCS3-mediated inhibition of JAK2 to activate STAT3, whereas neural progenitor cells (lacking BMX) are regulated by SOCS3, providing the molecular basis for GSC-selective targeting. Ibrutinib pharmacological inhibition, shRNA, SOCS3 epistasis analysis, phospho-signaling assays, intracranial tumor models combined with radiotherapy Science translational medicine High 29848664
2018 AR directly suppresses BMX gene expression by binding to the BMX gene locus; upon androgen deprivation, BMX expression increases and contributes to castration-resistant prostate cancer by phosphorylating the pYY activation loop motif of multiple receptor tyrosine kinases; ibrutinib and BMX-IN-1 inhibition markedly enhanced response to castration in xenograft models. AR ChIP demonstrating binding at BMX locus, anti-pYpY substrate antibody validation, RNAi KD, xenograft model with castration + BMX inhibitor Cancer research High 30012673
2020 BMX specifically phosphorylates PAR1 (protease-activated receptor-1), promoting PAR1 internalization and signal deactivation in endothelial cells; BMX loss increases thrombin-mediated endothelial permeability 2–3 fold; pharmacological PAR1 antagonism rescues BMX-KO-mediated vascular leakage in sepsis models. BMX-KO mice, cecal ligation/puncture sepsis model, transendothelial resistance assay, biochemical PAR1 phosphorylation and internalization assays, PAR1 antagonist rescue Circulation research High 31910739
2021 Fas signaling in adipocytes promotes NF-κB and MAPK pathway activation and inflammatory cytokine release (TNFα, IL-6) through a direct interaction between Fas (at Tyr189) and the SH2 domain of Bmx; disrupting this Fas–Bmx interaction attenuates adipocyte inflammation. Co-immunoprecipitation, site-specific Fas and Bmx SH2 mutants, cytokine ELISA, NF-κB/MAPK signaling assays Cancer letters Medium 34536556
2023 BMX directly interacts with 3β-hydroxysteroid dehydrogenase-1 (3βHSD1) and phosphorylates it at tyrosine 344 (Y344); Y344 phosphorylation is required for 3βHSD1 catalytic activity and generation of androgen biosynthesis intermediates (Δ4, 3-keto substrates for 5α-reductase and aromatase); in vivo blockade of Y344 phosphorylation inhibits castration-resistant prostate cancer growth. Co-immunoprecipitation, site-directed mutagenesis (Y344), in vitro kinase assay, patient tissue phosphorylation analysis, in vivo CRPC model The Journal of clinical investigation High 36647826
2010 Etk/BMX binds to PAR1 C-tail residues 378–384 via its PH domain, enabling subsequent Shc association; the Etk-PAR1 interaction is required for PAR1-induced invasion through Matrigel; knockdown of Etk inhibits PAR1-induced MDA-MB-435 cell migration, establishing the PAR1 C-tail as a scaffold for Etk/Shc complex assembly. Antibody array, co-immunoprecipitation, PAR1 C-tail Y/A and 7A mutants, Matrigel invasion assay, siRNA knockdown, in vivo xenograft PloS one High 20559570
2004 Bmx is a downstream effector of Rap1 in VEGF-induced endothelial cell signaling; VEGF treatment induces formation of a Rap1/Bmx complex (confirmed by co-immunoprecipitation); VEGF promotes Bmx recruitment to CAS scaffolding protein; dominant-negative Rap1 prevents Rap1/Bmx complex formation; Bmx kinase inhibition blocks VEGF-induced cell migration. Antibody array, co-immunoprecipitation, dominant-negative Rap1, Bmx kinase inhibitor, migration assay Biochemical and biophysical research communications Medium 15207703
2020 X-ray crystal structure of BMX covalently inhibited at Cys496 reveals key interactions with Lys445 that hamper ATP catalysis and a DFG-out-like inactive conformation; the structure guides design of potent selective BMX inhibitors. X-ray crystallography, covalent inhibitor design, molecular dynamics, kinome selectivity profiling, cellular target engagement assay RSC chemical biology High 34458764

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2001 The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species. BioEssays : news and reviews in molecular, cellular and developmental biology 237 11340625
2011 Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer cell 231 21481791
1998 Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America 210 9520419
1994 BMX, a novel nonreceptor tyrosine kinase gene of the BTK/ITK/TEC/TXK family located in chromosome Xp22.2. Oncogene 171 7970727
2001 Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Molecular and cellular biology 157 11713275
2003 Etk/Bmx transactivates vascular endothelial growth factor 2 and recruits phosphatidylinositol 3-kinase to mediate the tumor necrosis factor-induced angiogenic pathway. The Journal of biological chemistry 135 14532277
2018 Ibrutinib inactivates BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance. Science translational medicine 122 29848664
2001 Regulation of the PH-domain-containing tyrosine kinase Etk by focal adhesion kinase through the FERM domain. Nature cell biology 121 11331870
2000 Etk, a Btk family tyrosine kinase, mediates cellular transformation by linking Src to STAT3 activation. Molecular and cellular biology 115 10688651
2002 Etk/Bmx as a tumor necrosis factor receptor type 2-specific kinase: role in endothelial cell migration and angiogenesis. Molecular and cellular biology 114 12370298
1997 The Bmx tyrosine kinase induces activation of the Stat signaling pathway, which is specifically inhibited by protein kinase Cdelta. Blood 100 9373245
2006 The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs. Oncogene 99 16186805
2001 Etk/Bmx tyrosine kinase activates Pak1 and regulates tumorigenicity of breast cancer cells. The Journal of biological chemistry 97 11382770
2019 Linc00173 promotes chemoresistance and progression of small cell lung cancer by sponging miR-218 to regulate Etk expression. Oncogene 93 31477834
2018 Long-term Lactobacillus rhamnosus BMX 54 application to restore a balanced vaginal ecosystem: a promising solution against HPV-infection. BMC infectious diseases 93 29304768
1998 Tec/Bmx non-receptor tyrosine kinases are involved in regulation of Rho and serum response factor by Galpha12/13. The EMBO journal 81 9755164
2006 Critical function of Bmx/Etk in ischemia-mediated arteriogenesis and angiogenesis. The Journal of clinical investigation 75 16932810
2001 Bmx tyrosine kinase has a redundant function downstream of angiopoietin and vascular endothelial growth factor receptors in arterial endothelium. Molecular and cellular biology 71 11416142
1997 Bmx tyrosine kinase is specifically expressed in the endocardium and the endothelium of large arteries. Circulation 68 9323053
1999 Etk/Bmx, a PH-domain containing tyrosine kinase, protects prostate cancer cells from apoptosis induced by photodynamic therapy or thapsigargin. Oncogene 66 10362360
2017 Etk Interaction with PFKFB4 Modulates Chemoresistance of Small-cell Lung Cancer by Regulating Autophagy. Clinical cancer research : an official journal of the American Association for Cancer Research 65 29208667
2008 Structure of Escherichia coli tyrosine kinase Etk reveals a novel activation mechanism. The EMBO journal 60 18497741
2010 Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells. Cancer research 56 20570899
2007 Bmx tyrosine kinase regulates TLR4-induced IL-6 production in human macrophages independently of p38 MAPK and NFkapp}B activity. Blood 56 18025155
2002 Coordinating Etk/Bmx activation and VEGF upregulation to promote cell survival and proliferation. Oncogene 56 12483534
2003 p130Cas Couples the tyrosine kinase Bmx/Etk with regulation of the actin cytoskeleton and cell migration. The Journal of biological chemistry 53 12832404
2002 Interaction between tyrosine kinase Etk and a RUN domain- and FYVE domain-containing protein RUFY1. A possible role of ETK in regulation of vesicle trafficking. The Journal of biological chemistry 53 11877430
2002 Selective activation of small GTPase RhoA by tyrosine kinase Etk through its pleckstrin homology domain. The Journal of biological chemistry 52 12023958
1999 Reconstitution of Btk signaling by the atypical tec family tyrosine kinases Bmx and Txk. The Journal of biological chemistry 52 10224128
2001 Functional interaction of caveolin-1 with Bruton's tyrosine kinase and Bmx. The Journal of biological chemistry 48 11751885
2020 BMX Represses Thrombin-PAR1-Mediated Endothelial Permeability and Vascular Leakage During Early Sepsis. Circulation research 44 31910739
2006 Tyrosine kinase Etk/BMX is up-regulated in human prostate cancer and its overexpression induces prostate intraepithelial neoplasia in mouse. Cancer research 44 16912182
2013 Discovery of a selective irreversible BMX inhibitor for prostate cancer. ACS chemical biology 42 23594111
2012 BMX and its role in inflammation, cardiovascular disease, and cancer. International reviews of immunology 41 22449076
2005 Human single-domain neutralizing intrabodies directed against Etk kinase: a novel approach to impair cellular transformation. Molecular cancer therapeutics 40 16276002
2005 Etk/Bmx mediates expression of stress-induced adaptive genes VEGF, PAI-1, and iNOS via multiple signaling cascades in different cell systems. American journal of physiology. Cell physiology 38 15788485
2016 EPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K/BMX/STAT3 signaling pathway. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 37 27101199
2014 Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor. Cell death & disease 37 25188519
2000 The Bmx tyrosine kinase is activated by IL-3 and G-CSF in a PI-3K dependent manner. Oncogene 37 10962576
1997 Predominant expression of murine Bmx tyrosine kinase in the granulo-monocytic lineage. Blood 37 9373244
2015 Endothelial Bmx tyrosine kinase activity is essential for myocardial hypertrophy and remodeling. Proceedings of the National Academy of Sciences of the United States of America 36 26430242
2004 Bi-directional regulation between tyrosine kinase Etk/BMX and tumor suppressor p53 in response to DNA damage. The Journal of biological chemistry 36 15355990
2017 Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia. The Journal of clinical investigation 35 29227282
2004 The Tyr-kinase inhibitor AG879, that blocks the ETK-PAK1 interaction, suppresses the RAS-induced PAK1 activation and malignant transformation. Cancer biology & therapy 35 14726663
2008 Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase. Bioorganic & medicinal chemistry letters 33 18667312
2015 BMX Negatively Regulates BAK Function, Thereby Increasing Apoptotic Resistance to Chemotherapeutic Drugs. Cancer research 32 25649765
2011 The tyrosine kinase BMX is an essential mediator of inflammatory arthritis in a kinase-independent manner. Journal of immunology (Baltimore, Md. : 1950) 32 21471444
2008 Etk/BMX, a Btk family tyrosine kinase, and Mal contribute to the cross-talk between MyD88 and FAK pathways. Journal of immunology (Baltimore, Md. : 1950) 32 18292575
2004 The role of tyrosine kinase Etk/Bmx in EGF-induced apoptosis of MDA-MB-468 breast cancer cells. Oncogene 32 14676838
2021 NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition. International journal of molecular sciences 31 34072831
2012 Cycling of Etk and Etp phosphorylation states is involved in formation of group 4 capsule by Escherichia coli. PloS one 31 22675501
2007 Activation of nonreceptor tyrosine kinase Bmx/Etk mediated by phosphoinositide 3-kinase, epidermal growth factor receptor, and ErbB3 in prostate cancer cells. The Journal of biological chemistry 31 17823122
2016 Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC. Molecular cancer therapeutics 30 27197306
2008 STAT3 activation in pressure-overloaded feline myocardium: role for integrins and the tyrosine kinase BMX. International journal of biological sciences 30 18612371
2017 BMX/Etk promotes cell proliferation and tumorigenicity of cervical cancer cells through PI3K/AKT/mTOR and STAT3 pathways. Oncotarget 29 28514765
2006 A novel role for protein-tyrosine kinase Etk from Escherichia coli K-12 related to polymyxin resistance. Research in microbiology 29 16814990
2004 Bmx tyrosine kinase transgene induces skin hyperplasia, inflammatory angiogenesis, and accelerated wound healing. Molecular biology of the cell 29 15229285
1996 BMX tyrosine kinase gene is expressed in granulocytes and myeloid leukaemias. British journal of haematology 28 8790141
1988 Transcriptional properties of BmX, a moderately repetitive silkworm gene that is an RNA polymerase III template. Molecular and cellular biology 28 2832730
2018 BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer. Cancer research 27 30012673
2017 miR-495 promotes the chemoresistance of SCLC through the epithelial-mesenchymal transition via Etk/BMX. American journal of cancer research 27 28401017
2016 Phosphorylation Impacts N-end Rule Degradation of the Proteolytically Activated Form of BMX Kinase. The Journal of biological chemistry 27 27601470
2008 Phylogeny of Tec family kinases identification of a premetazoan origin of Btk, Bmx, Itk, Tec, Txk, and the Btk regulator SH3BP5. Advances in genetics 27 19161832
2001 Proteolytic activation of ETK/Bmx tyrosine kinase by caspases. The Journal of biological chemistry 27 11278797
2012 Deletion of the endothelial Bmx tyrosine kinase decreases tumor angiogenesis and growth. Cancer research 26 22593188
2010 Etk/Bmx regulates proteinase-activated-receptor1 (PAR1) in breast cancer invasion: signaling partners, hierarchy and physiological significance. PloS one 26 20559570
2014 BMX acts downstream of PI3K to promote colorectal cancer cell survival and pathway inhibition sensitizes to the BH3 mimetic ABT-737. Neoplasia (New York, N.Y.) 24 24709422
2013 Mini-review: bmx kinase inhibitors for cancer therapy. Recent patents on anti-cancer drug discovery 24 23198769
2013 Tyrosine kinase BMX phosphorylates phosphotyrosine-primed motif mediating the activation of multiple receptor tyrosine kinases. Science signaling 23 23716717
2008 Expression of tyrosine kinase Etk/Bmx and its relationship with AP-1- and NF-kappaB-associated proteins in hepatocellular carcinoma. Oncology 23 18196928
2019 BMX activates Wnt/β-catenin signaling pathway to promote cell proliferation and migration in breast cancer. Breast cancer (Tokyo, Japan) 22 31728872
2023 BMX controls 3βHSD1 and sex steroid biosynthesis in cancer. The Journal of clinical investigation 21 36647826
2014 The expression and role of tyrosine kinase ETK/BMX in renal cell carcinoma. Journal of experimental & clinical cancer research : CR 21 24606948
2008 Loss of Bmx nonreceptor tyrosine kinase prevents pressure overload-induced cardiac hypertrophy. Circulation research 21 18988895
2023 The X-linked Becker muscular dystrophy (bmx) mouse models Becker muscular dystrophy via deletion of murine dystrophin exons 45-47. Journal of cachexia, sarcopenia and muscle 20 36628607
2021 Fas signaling in adipocytes promotes low-grade inflammation and lung metastasis of colorectal cancer through interaction with Bmx. Cancer letters 20 34536556
2020 Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK. International journal of molecular sciences 20 33291717
2009 Non-receptor tyrosine kinase Etk regulation of drug resistance in small-cell lung cancer. European journal of cancer (Oxford, England : 1990) 20 20004564
2008 Bmx regulates LPS-induced IL-6 and VEGF production via mRNA stability in rheumatoid synovial fibroblasts. Biochemical and biophysical research communications 20 18402776
2015 NBM-T-BMX-OS01, an Osthole Derivative, Sensitizes Human Lung Cancer A549 Cells to Cisplatin through AMPK-Dependent Inhibition of ERK and Akt Pathway. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 19 26065336
2019 BMX-ARHGAP fusion protein maintains the tumorigenicity of gastric cancer stem cells by activating the JAK/STAT3 signaling pathway. Cancer cell international 18 31130822
2016 Topically applied manganese-porphyrins BMX-001 and BMX-010 display a significant anti-inflammatory response in a mouse model of allergic dermatitis. Archives of dermatological research 18 27709295
2013 Anti-cancer activity of an osthole derivative, NBM-T-BMX-OS01: targeting vascular endothelial growth factor receptor signaling and angiogenesis. PloS one 18 24312323
2014 Current understanding of tyrosine kinase BMX in inflammation and its inhibitors. Burns & trauma 16 27602372
2001 Etk/Bmx activation modulates barrier function in epithelial cells. American journal of physiology. Cell physiology 16 11350762
2017 Discovery of 2-((3-Acrylamido-4-methylphenyl)amino)-N-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-BMX-078) as a Highly Potent and Selective Type II Irreversible Bone Marrow Kinase in the X Chromosome (BMX) Kinase Inhibitor. Journal of medicinal chemistry 15 28140585
2011 Tyrosine kinase Etk/BMX protects nasopharyngeal carcinoma cells from apoptosis induced by radiation. Cancer biology & therapy 14 21339702
2023 Vamorolone improves Becker muscular dystrophy and increases dystrophin protein in bmx model mice. iScience 12 37534133
2014 Identification of a novel gene fusion (BMX-ARHGAP) in gastric cardia adenocarcinoma. Diagnostic pathology 12 25499959
2010 Non-receptor tyrosine kinase Etk is involved in the apoptosis of small cell lung cancer cells. Experimental and molecular pathology 12 20206622
2004 Bmx, a member of the Tec family of nonreceptor tyrosine kinases, is a novel participant in pharmacological cardioprotection. American journal of physiology. Heart and circulatory physiology 12 15191890
2013 NBM-T-L-BMX-OS01, Semisynthesized from Osthole, Is a Novel Inhibitor of Histone Deacetylase and Enhances Learning and Memory in Rats. Evidence-based complementary and alternative medicine : eCAM 11 23606881
2022 Ibrutinib Inhibits BMX-Dependent Endothelial VCAM-1 Expression In Vitro and Pro-Atherosclerotic Endothelial Activation and Platelet Adhesion In Vivo. Cellular and molecular bioengineering 10 35611166
2022 BMX, a specific HDAC8 inhibitor, with TMZ for advanced CRC therapy: a novel synergic effect to elicit p53-, β-catenin- and MGMT-dependent apoptotic cell death. Cell communication and signaling : CCS 10 36575468
2014 The influence of BMX gene polymorphisms on clinical symptoms after mild traumatic brain injury. BioMed research international 10 24860816
2022 BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors. Blood advances 9 35797240
2020 Structural and biophysical insights into the mode of covalent binding of rationally designed potent BMX inhibitors. RSC chemical biology 9 34458764
2017 Discovery of (R)-5-(benzo[d][1,3]dioxol-5-yl)-7-((1-(vinylsulfonyl)pyrrolidin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (B6) as a potent Bmx inhibitor for the treatment of NSCLC. Bioorganic & medicinal chemistry letters 9 28734581
2011 Suppression of Etk/Bmx protects against ischemic brain injury. Cell transplantation 9 21929872
2004 Bmx is a downstream Rap1 effector in VEGF-induced endothelial cell activation. Biochemical and biophysical research communications 9 15207703